As CEO Mike Duftar noted in the conference call transcript, products are sold according to their labels, not single open-label head-to-head trials
Lu Z, Liu J, Zhao L, Wang C, Shi F, Li Z, et al
nevertheless, many clinical trials assessing the effectiveness and safety of NAD+-replacement therapy or augmentation in the context of human disease and aging have recently been completed, and many more are currently underway
Retrieved 2026-05-24.
Therefore, we believe that updating the payment rates based on ASP data will more likely result in payment rates that reflect the changing dynamics of the market rather than anchoring the cost to the initial payment rate for CY 2026 based on data ( collected prior to the implementation of this policy
Thn trng vi ph n c thai hoc ang cho con b, tr em di 12 tui Lu Thc phm ny khng phi l thuc, khng c tc dng thay th thuc cha bnh